Market cap
$186 Mln
Recently Viewed
Clear AllMarket cap
$186 Mln
Revenue (TTM)
$237 Mln
P/E Ratio
11
P/B Ratio
2.1
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
0.2 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
4.7
Debt to Equity
0.1
Book Value
$0.4
EPS
$0.1
Face value
--
Shares outstanding
241,861,120
CFO
$-333.45 Mln
EBITDA
$-354.93 Mln
Net Profit
$-414.47 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Vaxart (VXRT)
| 123.8 | 27.3 | 32.8 | 75.2 | -1.8 | -41.0 | -26.8 |
|
BSE Sensex*
| -9.2 | 6.9 | -6.5 | -4.2 | 8.0 | 9.1 | 11.6 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Vaxart (VXRT)
| -48.0 | 15.5 | -40.4 | -84.7 | 9.8 | 1,529.1 | -81.4 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Vaxart (VXRT)
|
0.8 | 186.2 | 237.3 | 16.3 | 8.3 | 22.3 | 11 | 2.1 |
| 74.8 | 10,475.8 | 1,091.0 | 202.3 | 31.6 | 31.3 | 46.8 | 18.4 | |
| 220.9 | 13,649.0 | 691.7 | -219.0 | -13.7 | 163.2 | -- | 78.1 | |
| 43.7 | 11,095.1 | 2,320.1 | 782.6 | 39.0 | 35.5 | 15.7 | 5.1 | |
| 87.6 | 11,613.4 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 266.0 | 7,831.1 | 389.1 | 204.8 | 41.5 | 18.9 | 38.9 | 6.4 | |
| 513.7 | 11,844.1 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 19.7 | |
| 417.5 | 11,924.8 | 2,678.3 | 460.4 | 21.1 | 103.2 | 26.2 | 19.9 | |
| 99.0 | 7,822.0 | 0.0 | -425.4 | -- | -36.7 | -- | 6.3 | |
| 324.2 | 9,029.2 | 0.0 | -303.3 | -- | -45.8 | -- | 10.3 |
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform. The company's product pipeline includes... norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; COVID-19 Vaccine, which is in Phase 2b clinical trial for the treatment of SARS-CoV-1, SARS-CoV-2, and Middle East respiratory syndrome coronavirus; Seasonal Influenza vaccine, which is in Phase 2 clinical trial, to treat H1N1 Influenza; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California. Read more
Senior VP & Chief Scientific Officer
Dr. Sean N. Tucker Ph.D.
Senior VP & Chief Scientific Officer
Dr. Sean N. Tucker Ph.D.
Headquarters
South San Francisco, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Vaxart Inc (VXRT) is $0.77 (NASDAQ) as of 01-May-2026 16:00 EDT. Vaxart Inc (VXRT) has given a return of -1.82% in the last 3 years.
The P/E ratio of Vaxart Inc (VXRT) is 11.00 times as on 01-May-2026.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
4.85
|
0.90
|
|
2024
|
-2.00
|
2.27
|
|
2023
|
-1.01
|
1.44
|
|
2022
|
-1.14
|
1.11
|
|
2021
|
-10.77
|
4.05
|
The 52-week high and low of Vaxart Inc (VXRT) are Rs 0.84 and Rs 0.26 as of 03-May-2026.
Vaxart Inc (VXRT) has a market capitalisation of $ 186 Mln as on 01-May-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Vaxart Inc (VXRT), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.